Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Byooviz
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Fylnetra
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Releuko
    • Renflexis
    • Retacrit
    • Rezvoglar
    • Riabni
    • Ruxience
    • Semglee
    • Trazimera
    • Truxima
    • Udenyca
    • Yusimry
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2023 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

SM Health Comm

Recent Posts

  • Advancing Global Harmonization of Biosimilar Evaluations March 27, 2023
  • Insulin Price Cuts and the Questions for the Biosimilar Market March 24, 2023
  • Which Ten Medicines Will Be Medicare’s First Drug Price Negotiation Targets? March 16, 2023
  • Coherus’ Struggling Picture Prior to Udenyca On-Body Injector Approval and Yusimry Launch March 14, 2023
  • How Much Does Provider Comfort With Biosimilar Prescribing Matter? February 23, 2023
  • FDA Seeking Help With Biosimilar Development Streamlining Process February 17, 2023
  • The Inflation Reduction Balancing Act on Rebate Clawbacks February 10, 2023
  • Sandoz Sends 351(k) BLA to FDA for First Denosumab Biosimilar February 8, 2023
  • Amgen Launches Amjevita® With Two WAC-Based Pricing Options February 1, 2023
  • Put Your Money Where Your Mouth Is January 24, 2023

Recent Comments

Celltrion's Pen… on The Implications of Celltrion’…
40th Biosimilar Appr… on FDA Approves Fresenius Kabi’s…
Biogen Announces Sub… on Tocilizumab Biosimilars Approa…
J&J Slaps Patent… on Ustekinumab Biosimilars Update
J&J Slaps Patent… on Preliminary Phase 3 Study Data…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Insulin Price Cuts and the Questions for the Biosimilar Market
  • Advancing Global Harmonization of Biosimilar Evaluations
  • Biosimilar Approval Status
  • The Evolution of the Biosimilars Market
  • A Conversation With Ian Henshaw
  • Which Ten Medicines Will Be Medicare’s First Drug Price Negotiation Targets?
  • Yusimry
  • Amgen Launches Amjevita® With Two WAC-Based Pricing Options
  • The Inflation Reduction Balancing Act on Rebate Clawbacks
  • FDA Seeking Help With Biosimilar Development Streamlining Process
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.